Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region

American Journal of Tropical Medicine and Hygiene

Volumn 65, Issue 5, 2001, Pages 405-413

  Durbin, A P ^a   Karron, R A ^a   Sun, W ^a   Vaughn, D W ^a   Reynolds, M J ^a   Perreault, J R ^a   Thumar, B ^a   Men, R ^a   Lai, C J ^a   Elkins, W R ^a   Chanock, R M ^a   Murphy, B R ^a   Whitehead, S S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DENGUE VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; NUCLEOTIDE;

3' UNTRANSLATED REGION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENGUE VIRUS; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE DELETION; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; NONHUMAN; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; RASH; RHESUS MONKEY; SEROCONVERSION; VIREMIA; VIRUS ATTENUATION; VIRUS GENOME; VIRUS RECOMBINANT;

EID: 0035211999     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2001.65.405     Document Type: Article

References (43)

1. Impact of dengue/dengue hemorrhagic fever on the developing world
2. A prospective study of dengue infections in Bangkok
3. Dengue and chikungunya virus infection in man in Thailand, 1962-1964. IV. Epidemiologic studies in the Bangkok metropolitan area
4. Risk factors in dengue shock syndrome
5. Recent advances in our knowledge of dengue and sandfly fever
6. Flaviviruses
7. Studies on dengue: Anti-dengue active immunization experiments in mice
8. Production of immunity to dengue with virus modified by propagation in mice
9. Attenuated living type 1 dengue vaccines
10. Dengue-3 (16562) PGMK 33 vaccine: Neurovirulence, viremia and immune responses in Macaca fascicularis
11. Dengue-2 vaccine: Virological, immunological, and clinical responses of six yellow fever-immune recipients
12. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): Clinical, immunological and biological responses in adult volunteers
13. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells
14. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans
15. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers
16. Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers
17. Live attenuated tetravalent dengue vaccine
18. Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus
19. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes
20. Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice
21. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine
22. Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4
23. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge
24. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates
25. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA 14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates
26. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: Analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys
27. The nucleotide sequence of dengue type 4 virus: Analysis of genes coding for nonstructural proteins
28. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses
29. A plaque reduction test for dengue virus neutralizing antibodies
30. Yellow fever/Japanese encephalitis chimeric viruses: Construction and biological properties
31. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3
32. Changes in the dengue virus major envelope protein on passaging and their localization on the three-dimensional structure of the protein
33. Dengue 2 vaccine: Dose response in volunteers in relation to yellow fever immune status
34. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers
35. Liver biochemical tests and dengue fever
36. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans
37. Detection of dengue virus RNA by reverse transcription-polymerase chain reaction in the liver and lymphoid organs but not in the brain in fatal human infection
38. Recovery of virus from the liver of children with fatal dengue: Reflections on the pathogenesis of the disease and its possible analogy with that of yellow fever
39. Invited commentary: Dengue lessons from Cuba
40. Effect of the attenuating deletion and of sequence alterations evolving in vivo on simian immunodeficiency virus C8-Nef function
41. Natural genetic exchanges between vaccine and wild poliovirus strains in humans
42. Widespread intraserotype recombination in natural populations of dengue virus